Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.

ABSTRACT: Lung cancer is the leading cause of cancer-related death across the world. Unlike lung adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted from targeted therapies. Although immunotherapy has significantly improved cancer patients' outcomes, the relatively low response rate and severe adverse events hinder the clinical application of this promising treatment in LSCC. Therefore, it is of vital importance to have a better understanding of the mechanisms underlying the pathogenesis of LSCC as well as the inner connection among different signaling pathways, which will surely provide opportunities for more effective therapeutic interventions for LSCC. In this review, new insights were given about classical signaling pathways which have been proved in other cance

SUBMITTER: Niu Z 

PROVIDER: S-EPMC9535022 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature